05-07-2025
Leerink Partners Keeps Their Buy Rating on Universal Health (UHS)
In a report released yesterday, Whit Mayo from Leerink Partners reiterated a Buy rating on Universal Health. The company's shares closed last Thursday at $184.53.
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Mayo covers the Healthcare sector, focusing on stocks such as Universal Health, UnitedHealth, and HCA Healthcare. According to TipRanks, Mayo has an average return of 2.7% and a 49.39% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Universal Health with a $229.09 average price target, implying a 24.15% upside from current levels. In a report released on June 24, Barclays also maintained a Buy rating on the stock with a $257.00 price target.
Based on Universal Health's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.1 billion and a net profit of $316.68 million. In comparison, last year the company earned a revenue of $3.84 billion and had a net profit of $261.83 million
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UHS in relation to earlier this year. Most recently, in May 2025, Maria Singer Ruderman, a Director at UHS sold 1,097.00 shares for a total of $210,042.59.
